Ordaos Bio: Funding, Investors & Team (Oct 2026)
Ordaōs is a human-enabled, machine-driven drug design company. Through partnership with industry and academia, the dedicated Ordaōs team leverages proprietary generative perception systems and reinforcement learning to create bespoke mini-proteins that help pharma and biotechs around the world deliver safer and more effective life-saving treatments in a fraction of the time of traditional discovery methods. Ordaōs does this by creating billions of proteins and evaluating their properties in silico, to reliably and repeatedly deliver de novo mini-proteins that achieve the requirements drug hunters only dream of. Ordaōs then proves its consistency and unparalleled efficacy by rigorously synthesizing and testing top-ranking sequences in vitro. The result is Ordaōs miniPRO™, a class of mini-proteins that threaten to revolutionize the role of proteins in drug discovery. miniPRO™ proteins provide the power and performance of antibodies, but are configurable, more stable, and easier to manufacture. By maximizing drug candidate delivery speed, novelty, and probability of clinical success, Ordaōs can provide the highest client confidence in every investigational new drug (IND) application. What’s more, clients that work with Ordaōs see a return on their investment in weeks, rather than months or years. Most importantly, Ordaōs miniPRO™ proteins help birth novel therapies that reduce patient suffering, improve health, and extend life.
Ordaos Bio has raised $18.8M across 3 funding rounds on record, the most recent an undisclosed round of $3.1M announced in Sep 2024.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ordaos Bio Company Profile and Key Stats
Latest funding round on record: Sep 2024.
Ordaos Bio Funding Rounds
Ordaos Bio raised $10.7M in an undisclosed round announced in Jun 2022.
2 months later, a Seed of $5.0M was announced in Aug 2022.
2.1 years later, an undisclosed round of $3.1M was announced in Sep 2024.
Ordaos Bio Founders and Leadership Team
Contact details for the Ordaos Bio team: 1 of 1 has an email address on file.
Start 14-day free trial →Ordaos Bio Funding Compared to Other Biotechnology Startups
Ordaos Bio's latest round of $3.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ordaos Bio in Biotechnology and Manhattan
Companies Similar to Ordaos Bio
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Ordaos Bio Funding FAQs
What does Ordaos Bio do?
Ordaōs is a human-enabled, machine-driven drug design company. Through partnership with industry and academia, the dedicated Ordaōs team leverages proprietary generative perception systems and reinforcement learning to create bespoke mini-proteins that help pharma and biotechs around the world deliver safer and more effective life-saving treatments in a fraction of the time of traditional discovery methods. Ordaōs does this by creating billions of proteins and evaluating their properties in silico, to reliably and repeatedly deliver de novo mini-proteins that achieve the requirements drug hunters only dream of. Ordaōs then proves its consistency and unparalleled efficacy by rigorously synthesizing and testing top-ranking sequences in vitro. The result is Ordaōs miniPRO™, a class of mini-proteins that threaten to revolutionize the role of proteins in drug discovery. miniPRO™ proteins provide the power and performance of antibodies, but are configurable, more stable, and easier to manufacture. By maximizing drug candidate delivery speed, novelty, and probability of clinical success, Ordaōs can provide the highest client confidence in every investigational new drug (IND) application. What’s more, clients that work with Ordaōs see a return on their investment in weeks, rather than months or years. Most importantly, Ordaōs miniPRO™ proteins help birth novel therapies that reduce patient suffering, improve health, and extend life.
How much funding has Ordaos Bio raised?
Ordaos Bio has raised $18.8M across 3 rounds on record. The most recent is an undisclosed round of $3.1M announced in Sep 2024.
When did Ordaos Bio last raise funding?
Ordaos Bio's most recent funding round on record is an undisclosed round of $3.1M, announced in Sep 2024.
Who founded Ordaos Bio?
FundedIQ lists David Longo (Founder) at Ordaos Bio.
Where is Ordaos Bio headquartered?
Ordaos Bio is based in Manhattan, New York, United States.
How many employees does Ordaos Bio have?
Ordaos Bio is in the 11-50 employee band.
How does Ordaos Bio's funding compare to other Biotechnology startups?
Ordaos Bio's latest round of $3.1M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Ordaos Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ordaos Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.